SCHEMBL221251

SCHEMBL221251

CC(C)N1CCC(N(CCCO)S(=O)(=O)CCNC(=O)c2ccc(Cl)s2)CC1

nearest known ligand 0.63

Predicted protein targets (top 3)

geneUniProtsupporting neighboursconfidence
▸ F10 P00742 10/20 0.63
▸ MAPK1 P28482 1/20 0.43
▸ SMN1; SMN2 Q16637 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL219860 0.95 F10 (0.65) F10MAPK1SMN1; SMN2
SCHEMBL221417 0.90 F10 (0.63) F10MAPK1SMN1; SMN2
SCHEMBL3879157 0.86 F10 (0.46) F10
SCHEMBL219743 0.86 F10 (0.63) F10MAPK1SMN1; SMN2
SCHEMBL219872 0.86 F10 (0.63) F10MAPK1SMN1; SMN2
SCHEMBL221193 0.85 F10 (0.69) F10MAPK1SMN1; SMN2
SCHEMBL222034 0.84 F10 (0.53) F10MAPK1SMN1; SMN2
SCHEMBL221616 0.84 F10 (0.60) F10MAPK1
SCHEMBL220422 0.84 F10 (0.56) F10MAPK1SMN1; SMN2
SCHEMBL220475 0.84 F10 (0.67) F10MAPK1SMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8088925-B2 low molecular weight factor Xa specific blood clotting inhibitors; less side effects; 5-Chloro-thiophene-2-carboxylic acid [2-(1-isopropyl-piperidin-4-ylsulfamoyl)-ethyl]-amide; thromboembolic diseases or restenosis; antithrombotic agents SANOFI-AVENTIS (FR) 2012-01-03 — — US claimed
US-8088925-B2 low molecular weight factor Xa specific blood clotting inhibitors; less side effects; 5-Chloro-thiophene-2-carboxylic acid [2-(1-isopropyl-piperidin-4-ylsulfamoyl)-ethyl]-amide; thromboembolic diseases or restenosis; antithrombotic agents SANOFI-AVENTIS (FR) 2012-01-03 — — US disclosed
Send feedback